The Drive with Peter Attia — Matt Kaeberlein

On: Rapamycin and dogs — man’s best friends?

Episode: 10

Date: August 2018

Key Subjects:

  • Involved in dog ageing research project:
    • Live in similar environment as humans.
    • Die from similar diseases as humans (although cancer is the most common in dogs, versus heart disease in humans).
  • Rapamycin is immunosuppressant (see mTOR write-up).
    • Reduces T cell proliferation on high doses (protective in organ transplants).
    • But, becomes immunoprotective on low doses / cycling.
    • Likely through enhanced stem cell function.
  • Rapamycin may delay ageing and also restore functionality.
    • Such as heart function.
  • Autophagy:
    • Difficult to measure.
    • Can be beneficial or detrimental.
    • Rapamycin seems to activate beneficial autophagy.
  • Cancer:
    • Ability of the body to detect cancer cells goes down with age as the immune function deteriorates.
    • Rapamycin (in proper dosage) can enhance the body’s immune surveillance.
  • Neurodegenerative diseases:
    • Diseases of aging.
    • Rapamycin may also be useful in halting the development of Alzheimer’s Disease.
    • Likely through autophagy, stopping protein accumulation.
  • Caloric restriction:
    • Rapamycin and caloric restriction both inhibit mTOR.
    • While there is some overlap between the tow, rapamycin likely covers a broader array of mTOR inhibition.
  • Metabolome:
    • Little know about interaction between rapamycin and the metabolome.
    • The decrease of intestinal barrier function with age causes inflammation.
    • Rapamycin may stop decrease of function and help lower chronic inflammation.

Key Takeaways:

  • -/-

Worth Listening:

  • 7/10

Leave a Reply